JP2002532432A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532432A5
JP2002532432A5 JP2000587794A JP2000587794A JP2002532432A5 JP 2002532432 A5 JP2002532432 A5 JP 2002532432A5 JP 2000587794 A JP2000587794 A JP 2000587794A JP 2000587794 A JP2000587794 A JP 2000587794A JP 2002532432 A5 JP2002532432 A5 JP 2002532432A5
Authority
JP
Japan
Prior art keywords
dose
erythropoietin
pharmaceutical composition
use according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000587794A
Other languages
English (en)
Japanese (ja)
Other versions
JP4750947B2 (ja
JP2002532432A (ja
Filing date
Publication date
Priority claimed from DE19857609A external-priority patent/DE19857609A1/de
Application filed filed Critical
Publication of JP2002532432A publication Critical patent/JP2002532432A/ja
Publication of JP2002532432A5 publication Critical patent/JP2002532432A5/ja
Application granted granted Critical
Publication of JP4750947B2 publication Critical patent/JP4750947B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000587794A 1998-12-14 1999-12-13 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 Expired - Fee Related JP4750947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
DE19857609.9 1998-12-14
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010283105A Division JP2011079860A (ja) 1998-12-14 2010-12-20 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用

Publications (3)

Publication Number Publication Date
JP2002532432A JP2002532432A (ja) 2002-10-02
JP2002532432A5 true JP2002532432A5 (enExample) 2006-12-21
JP4750947B2 JP4750947B2 (ja) 2011-08-17

Family

ID=7891015

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000587794A Expired - Fee Related JP4750947B2 (ja) 1998-12-14 1999-12-13 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用
JP2010283105A Withdrawn JP2011079860A (ja) 1998-12-14 2010-12-20 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010283105A Withdrawn JP2011079860A (ja) 1998-12-14 2010-12-20 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用

Country Status (26)

Country Link
US (1) US7514072B1 (enExample)
EP (1) EP1140139B2 (enExample)
JP (2) JP4750947B2 (enExample)
KR (1) KR100774827B1 (enExample)
CN (1) CN1187085C (enExample)
AT (1) ATE253932T1 (enExample)
AU (1) AU766216C (enExample)
BG (1) BG65417B1 (enExample)
BR (1) BR9916197A (enExample)
CA (1) CA2353553C (enExample)
DE (2) DE19857609A1 (enExample)
DK (1) DK1140139T4 (enExample)
ES (1) ES2211218T5 (enExample)
HK (1) HK1042655B (enExample)
HU (1) HUP0104709A3 (enExample)
ID (1) ID29107A (enExample)
IL (2) IL143579A0 (enExample)
MX (1) MXPA01005971A (enExample)
NO (1) NO330079B1 (enExample)
NZ (1) NZ541591A (enExample)
PL (1) PL202483B1 (enExample)
PT (1) PT1140139E (enExample)
RO (1) RO121409B1 (enExample)
RU (1) RU2242991C2 (enExample)
WO (1) WO2000035475A2 (enExample)
ZA (1) ZA200104626B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404226B2 (en) 2002-07-03 2013-03-26 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
KR20070008519A (ko) 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
CA2543242C (en) * 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
EP2004211A4 (en) 2006-03-17 2010-07-07 Stem Cell Therapeutics Corp DOSEERSCHEMATA FOR LH OR HCG AND EPO FOR THE TREATMENT OF NEUROLOGICAL DISEASES
CA2654154A1 (en) * 2006-06-07 2007-12-13 The University Of Tokushima Treatment of ischemic diseases using erythropoietin
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
HK1000547A1 (en) 1989-12-22 1998-04-03 Merck Serono Sa Endogenous gene expression modification with regulatory element by way of homologous recombination
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
JP3537151B2 (ja) * 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
KR960701650A (ko) 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PL352223A1 (en) 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404226B2 (en) 2002-07-03 2013-03-26 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Similar Documents

Publication Publication Date Title
JP2002532432A5 (enExample)
ECSP056076A (es) Sistema de suministro para droga y terapia celular
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
JP2004526758A5 (enExample)
DE799037T1 (de) Verfahren und mittel zur behandlung der allergischen rhinitis und anderer erkrankungen mittels descarboethoxyloratadin
ATE429904T1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
CA2353553A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
JP2003514025A5 (enExample)
JP2002530353A5 (enExample)
JP2009500045A5 (enExample)
JP2003528919A5 (enExample)
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
CA2519789A1 (en) Aplidine for multiple myeloma treatment
RU96115219A (ru) Способ лечения больных сахарным диабетом
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
CA2091134A1 (en) Therapeutic agent for threatened abortion
NO920855L (no) Medikamentinneholdende matrise
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
JP2004503471A5 (enExample)
RU2004121780A (ru) Способ лечения
JP2002529515A5 (enExample)